Provided by Tiger Fintech (Singapore) Pte. Ltd.

Greenwich Lifesciences Inc

11.57
+0.08000.70%
Post-market: 11.570.00000.00%16:11 EDT
Volume:37.27K
Turnover:427.81K
Market Cap:154.67M
PE:-9.14
High:11.74
Open:11.49
Low:11.16
Close:11.49
Loading ...

Greenwich Lifesciences Inc. Changes Auditors, Appoints MaloneBailey LLP After Dismissing RBSM LLP

Reuters
·
25 Jul

Greenwich LifeSciences Announces Global Expansion of Phase III Trial for Promising Breast Cancer Vaccine GLSI-100

Reuters
·
27 Jun

Greenwich Lifesciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
24 May

Greenwich Lifesciences Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
22 May

Greenwich LifeSciences Q1 EPS $(0.25) Down From $(0.19) YoY

Benzinga
·
21 May

Greenwich Lifesciences Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
17 May

Greenwich Lifesciences Inc. Delays Quarterly Financial Report, Filing Expected by May 20

Reuters
·
16 May

Top Executive Makes Bold Investment in Greenwich LifeSciences!

TIPRANKS
·
30 Apr

Greenwich LifeSciences CEO Makes Bold Stock Purchase!

TIPRANKS
·
23 Apr

Greenwich LifeSciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
21 Apr

Greenwich Lifesciences Inc expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
12 Apr

Greenwich LifeSciences CEO Makes Bold Stock Purchase!

TIPRANKS
·
09 Apr

BRIEF-Greenwich Lifesciences Provides Global Update On Flamingo-01

Reuters
·
03 Apr

Greenwich LifeSciences provides global update on FLAMINGO-01

TIPRANKS
·
03 Apr

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

GlobeNewswire
·
03 Apr

BUZZ-U.S. STOCKS ON THE MOVE-M-tron, Rocket Companies, TKO Group

Reuters
·
03 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Greenwich, CoreWeave, Blackberry

Reuters
·
02 Apr

BUZZ-Greenwich rises on immune response data from breast cancer therapy trial

Reuters
·
02 Apr

BRIEF-Greenwich Lifesciences Announces Positive Immune Response Data From FLAMINGO-01 Phase III Clinical Trial

Reuters
·
02 Apr

Recent 15% decline may not have gone down well with Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders who've been purchasing recently

Simply Wall St.
·
01 Apr